Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;60(4):497-501.
doi: 10.2967/jnumed.118.216853. Epub 2018 Oct 5.

Evidence of Local Concentration of α-Particles from 211At-Labeled Antibodies in Liver Metastasis Tissue

Affiliations

Evidence of Local Concentration of α-Particles from 211At-Labeled Antibodies in Liver Metastasis Tissue

Satoshi Kodaira et al. J Nucl Med. 2019 Apr.

Abstract

We investigated the local concentration of α-particles from 211At-labeled trastuzumab antibodies against human epidermal growth factor receptor type 2 antigens in liver metastasis tissue of mice. Methods: Mice carrying metastatic cancer in their liver were injected with 211At-agent. After 12 h, the liver was removed and sliced, and 2 tissue samples of liver tissues without lesions and one containing metastatic lesions were mounted on the CR-39 plastic nuclear track detector. Microscope images of the tissues on the CR-39 were acquired. After irradiation for 31 h, the tissues were removed from the CR-39. A microscope image of α-particle tracks on the CR-39 was acquired after chemical etching. The positions of each tissue sample and the emitted α-particle tracks were adjusted to the same coordinates. Results: The positional distribution of α-particle tracks emitted from 211At was consistent within the tissue. The α-particle tracks were mainly allocated in the tumor region of the tissue. The absorbed dose in individual cells segmented by 10-μm intervals was obtained by the spectroscopic analysis of the linear-energy-transfer spectrum. The concentration efficiency-the track density ratio of α-particle tracks in the necrotized tissue, which was the tumor region, to the normal tissue-was found to be 6.0 ± 0.2. In the tumor region, the high-linear-energy-transfer α-particles deposited a large enough dose to cause lethal damage to the cancer cells. Conclusion: The total absorbed dose ranged from 1 to 7 Gy with a peak at around 2 Gy, which would correspond to a 2-3 times higher biologically equivalent dose because of the high relative biological effectiveness of the α-particles emitted from 211At.

Keywords: 211At radionuclide; autoradiography; dose distribution; microscopy; radioimmunotherapy; α-particle.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
(A) Photomicrograph of sliced tissues; left tissue has specifically localized tumors. (B) Scatterplot of detected α-particle tracks on CR-39. (C) Superposition of tissue image and scatterplot of α-particle tracks. (D) Contour map of α-particle track density in binned positions (Δx, Δy) with 50-μm intervals.
FIGURE 2.
FIGURE 2.
LET spectrum of observed α-particles.
FIGURE 3.
FIGURE 3.
Histogram of observed local absorbed dose for t = 12–43 h, estimated dose corrected by half-life of 211At decay for t = 0–12 h, and estimated total dose for t = 0–43 h. Doses are given in cell scale size (10 μm).
FIGURE 4.
FIGURE 4.
Contour map of total local absorbed dose in binned positions (Δx, Δy) with 10-μm intervals.

References

    1. Newman HC, Prise KM, Folkard M, Michael BD. DNA double-strand break distributions in x-ray and alpha-particle irradiated V79 cells: evidence for non-random breakage. Int J Radiat Biol. 1997;71:347–363. - PubMed
    1. Bruland ØS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s–6257s. - PubMed
    1. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–594. - PubMed
    1. Nilsson S, Larsen RH, Fosså SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–4459. - PubMed
    1. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–686. - PubMed

Publication types